Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  zoledronic acid
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-24 of 24 for your search:
Start Over
Prolonged Protection From Bone Disease in Multiple Myeloma
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: NMSG 22/14, 2014-001121-32, NCT02286830
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: CDR0000455008, MRC-STAMPEDE, EU-205102, MRC-PR08, ISRCTN78818544, EUDRACT-2004-000193-31, NCT00268476
Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 382, NCT00691236
Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Phase: Phase III, Phase II
Type: Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: MG2009_01, NCT01006395
Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN-080520C, NCT01344967
Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: jzhang2, NCT01654367
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HOBOE, NCT00412022
Combination Chemotherapy With or Without Zoledronic Acid in Treating Patients With Osteosarcoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 5 to 50
Sponsor: Other
Protocol IDs: CDR0000543987, FRE-FNCLCC-SARCOME-09-0603, FRE-FNCLCC-OS-2006, NOVARTIS-FRE-FNCLCC-SARCOME-09, CHUGAI-FRE-FNCLCC-SARCOME-09-0, EU-20729, EUDRACT-2006-00337727, NOVARTIS-FRE-FNCLCC-SARCOME-09-0603, CHUGAI-FRE-FNCLCC-SARCOME-09-0603, SARCOME 09/0603, NCT00470223
Study in Localized and Disseminated Ewing Sarcoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 4 to 50
Sponsor: Other
Protocol IDs: 108128, EudraCT number: 2008-003658-13, NCT00987636
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20090482, NCT01345019
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 114273, NCT01920568
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: V0706, NCT00601003
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 0078-09-EMC, NCT01067989
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: VICC BMT 1020, NCT01215344
Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: SRFB-021, LCI-10-10-20, NCT01259193
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Zo-neo2011, NCT01472146
Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients
Phase: Phase II
Type: Supportive care
Status: Approved-not yet active
Age: 20 and over
Sponsor: Other
Protocol IDs: Sev-4-2014-0440, NCT02231476
Pre-operative Zoledronate in Triple Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IRFMN-BRC-6591, NCT02347163
ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma
Phase: Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BRD 10/2-S, NCT01219790
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 10192, NCI-2011-02137, NCT01409811
Study to Assess Incidence of ONJ in Pts With Bone Mets Starting Zoledronic Acid Treatment
Phase: No phase specified
Type: Supportive care
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: 2111-094, NCT01488851
Bone Loss Treatment From Adjuvant Zoledronate Efficacy
Phase: No phase specified
Type: Supportive care
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 20110618GD, NCT01623908
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BCC-HEM-11-003, NCT01772719
Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: 0S-13-3, NCI-2014-00207, P30CA014089, NCT02069340
Start Over